CAR-M1 Macrophage
It is Gene-Therapy for solid tumors and effective for treating solid tumor. This technology provides cost efficient off-the-shelf gene therapy
Negotiable Min Order Quantity Unit
- Required Quantity
-
- Place of Origin
- South Korea
- Payment Terms
- T/T
- Production method
- Available
- Shipping / Lead Time
- Negotiable / Negotiable
- Keyword
- solid tumor, car-m1 macrophage, gene therapy, off-the-shelf
- Category
- Medicines
Seoul National University R&DB Foundation
- Membership
- VIP
- Recent Visit
- Dec 13, 2024
- Country / Year Established
-
South Korea
/
2003
- Business type
- Others
- Verified Certificate
-
2
| Product name | CAR-M1 Macrophage | Certification | - |
|---|---|---|---|
| Category | Medicines | Material | - |
| Keyword | solid tumor , car-m1 macrophage , gene therapy , off-the-shelf | Unit Size | - |
| Brand name | - | Unit Weigh | - |
| origin | South Korea | Stock | 1 |
| Supply type | Available | HS code | - |
Product Information
CAR-M1 Macrophage
- It is Gene-Therapy for solid tumors and effective for treating solid tumor. This technology provides cost efficient off-the-shelf gene therapy, triggers innate and adaptive immunity. In addtion, it is less likely to cause toxic side effects.
- Nanocomplexes comprising macrophage-targeting nanocarriers and CAR-interferon-γ-ncoding plasmid DNA induce macrophages to express CAR and anti-tumoral M1 phenotype in vivo
- Induced CAR-M1 macrophages have the innate behavior of migrating to cancer tissues and phagocytosing cancer cells
- Macrophages can present antigens of phagocytosed tumor cells which activate cancer cell-specific cytotoxic T cells
- CAR-M1 macrophage for solid tumor treatment is more effective than CAR-T and Car NK Cell therapy
- Activity of CAR cells(CAR-M1 Macrophage) in immunisuppressive TME is higher than CAR-T and Car NK Cell's activity
- Product Info Attached File
B2B Trade
| Price (FOB) | Negotiable | transportation | Negotiation Other |
|---|---|---|---|
| MOQ | Negotiable | Leadtime | Negotiable |
| Payment Options | T/T | Shipping time | Negotiable |
Seoul National University R&DB Foundation
- Country / Year Established
-
South Korea
/
2003
- Membership
- VIP
- Recent Visit
- Dec 13, 2024
- Business type
- Others
-
2
- President
- Jaeyoung KIM
- Address
- Kwanak-ro 1, Gwanak-gu, Seoul, Korea
- Product Category
- Other Analyzers
- Year Established
- 2003
- No. of Total Employees
- 101-500
- Company introduction
-
- Main Markets
-
South Korea
- Main Product
_2.jpg "ideaocean")
Related Products
PSMA-DGUL
BioDesign_Protein drug design platform
EG-R mRNA Delivery System
Botulinum toxin
_2.jpg "VINIX ORAL DISSOLVING FILM 50mg_100mg_Sildenafil_50mg_100mg__2")
VINIX ORAL DISSOLVING FILM 50mg,100mg(SILDENAFIL 50mg, 100mg)
